<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04085666</url>
  </required_header>
  <id_info>
    <org_study_id>CDX6114-002</org_study_id>
    <nct_id>NCT04085666</nct_id>
  </id_info>
  <brief_title>Pharmacodynamics, Safety, Tolerability and Pharmacokinetics of CDX-6114 in Patients With Phenylketonuria (PKU)</brief_title>
  <official_title>A Phase 1, Multi-center, Randomized, Double-blind, Placebo-controlled, Cross-over Study to Evaluate the Pharmacodynamics, Safety, Tolerability and Pharmacokinetics of a Single Oral Dose of CDX-6114 in Patients With Phenylketonuria (PKU).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nestlé</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nestlé</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is an international, multi-center, randomized, double-blind, placebo-controlled,&#xD;
      two-treatment, two-period cross-over study to evaluate the pharmacodynamics, safety,&#xD;
      tolerability and pharmacokinetics of a single oral dose of CDX-6114 in patients with&#xD;
      phenylketonuria (PKU).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 1, 2019</start_date>
  <completion_date type="Actual">August 30, 2020</completion_date>
  <primary_completion_date type="Actual">June 30, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in concentration of post parandial plasma level of Phe will be summarized over time for each treatment</measure>
    <time_frame>Within 30 minutes, within 10 minutes and immediately prior to dosing, and then at 15 minutes, 30 minutes, 1hours, 1.5, 2,4 and 5hours after dosing on both Day 1 and Day 8</time_frame>
    <description>Blood samples will be collected at the following time points to determine the postprandial plasma levels of Phe following single does of CDX-6114</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in concentration of post parandial plasma level of CA will be summarized over time for each treatment</measure>
    <time_frame>Within 30 minutes, within 10 minutes and immediately prior to dosing, and then at 15 minutes, 30 minutes, 1hours, 1.5, 2,4 and 5hours after dosing on both Day 1 and Day 8</time_frame>
    <description>Blood samples will be collected at the following time points to determine the postprandial plasma levels of CA following single does of CDX-6114</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in the peak Phe concentration in Plasma will be summarized by treatment</measure>
    <time_frame>Within 30 minutes, within 10 minutesand immediately prior to dosing, and then at 15 minutes, 30 minutes, 1, 1.5, 2, 4 and 5hours after dosing on both Day 1 and Day 8</time_frame>
    <description>Blood samples will be collected at the following time points to determine the Peak Phe plasma concentration follwoing a single, oral dose of CDX-6114</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in the peak CA concentration in Plasma will be summarized by treatment</measure>
    <time_frame>Within 30 minutes, within 10 minutesand immediately prior to dosing, and then at 15 minutes, 30 minutes, 1, 1.5, 2, 4 and 5hours after dosing on both Day 1 and Day 8</time_frame>
    <description>Blood samples will be collected at the following time points to determine the Peak CA plasma concentration following a single, oral dose of CDX-6114</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phe Area under the plasma concentration versus time curve (AUC) , over a 5-hour period, following dosing and the standardized breakfast</measure>
    <time_frame>Within 30 minutes, within 10 minutesand immediately prior to dosing, and then at 15 minutes, 30 minutes, 1, 1.5, 2, 4 and 5hours after dosing on both Day 1 and Day 8</time_frame>
    <description>Blood samples will be collected at the following time points to determine the Phe AUC following a single, oral dose of CDX-6114</description>
  </primary_outcome>
  <primary_outcome>
    <measure>CA Area under the plasma concentration versus time curve (AUC) , over a 5-hour period, following dosing and the standardized breakfast</measure>
    <time_frame>Within 30 minutes, within 10 minutesand immediately prior to dosing, and then at 15 minutes, 30 minutes, 1, 1.5, 2, 4 and 5hours after dosing on both Day 1 and Day 8</time_frame>
    <description>Blood samples will be collected at the following time points to determine the CA AUC following a single, oral dose of CDX-6114</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events (AEs) will be measured</measure>
    <time_frame>Within 30 minutes, within 10 minutes and immediately prior to dosing, and then at 15 minutes, 30 minutes, 1, 1.5, 2, 4 and 5hours after dosing on both Day 1 and Day 8</time_frame>
    <description>The safety and tolerability of CDX-6114 following single dose oral administration assesed by Adverse events monitoring</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The serum levels of CDX-6114 will be summarized descriptively over time</measure>
    <time_frame>Within 30 minutes, within 10 minutes and immediately prior to dosing, and then at 15 minutes, 30 minutes, 1, 1.5, 2, 4 and 5hours after dosing on both Day 1 and Day 8</time_frame>
    <description>Blood will be collected for pharmacokinetic analysis of CDX-6114 at the following time points follwoing a single oral dose of CDX-6114</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute values and changes from baseline in blood pressure measurements will be summarized over time for each treatment</measure>
    <time_frame>Within 30 minutes prior to dosing, and then at 15 minutes, 30 minutes, 1, 1.5, 2, 4 and 5hours after dosing on both Day 1 and Day 8.</time_frame>
    <description>The safety and tolerability of CDX-6114 following single dose oral administration assesed by blood pressure monitoring</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute values and changes from baseline in Heart rate measurements will be summarized over time for each treatment</measure>
    <time_frame>Within 30 minutes prior to dosing, and then at 15 minutes, 30 minutes, 1, 1.5, 2, 4 and 5hours after dosing on both Day 1 and Day 8.</time_frame>
    <description>The safety and tolerability of CDX-6114 following single dose oral administration assesed by Heart rate monitoring</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute values and changes from baseline in Respiratory rate measurements will be summarized over time for each treatment</measure>
    <time_frame>Within 30 minutes prior to dosing, and then at 15 minutes, 30 minutes, 1, 1.5, 2, 4 and 5hours after dosing on both Day 1 and Day 8.</time_frame>
    <description>The safety and tolerability of CDX-6114 following single dose oral administration assesed by Respiratory rate monitoring</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute values and changes from baseline in body temperature (in Fahrenheit or Celsius) measurements will be summarized over time for each treatment</measure>
    <time_frame>Within 30 minutes prior to dosing, and then at 15 minutes, 30 minutes, 1, 1.5, 2, 4 and 5hours after dosing on both Day 1 and Day 8.</time_frame>
    <description>The safety and tolerability of CDX-6114 following single dose oral administration assesed by Body temperature monitoring</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute values and changes from baseline in 12 lead Electrocardiogram (ECG) measurements will be summarized over time for each treatment</measure>
    <time_frame>Within 30 minutes prior to dosing, and then at 15 minutes, 30 minutes, 1, 1.5, 2, 4 and 5hours after dosing on both Day 1 and Day 8.</time_frame>
    <description>The safety and tolerability of CDX-6114 following single dose oral administration assesed by 12 lead ECG including P Wave, QRS Complex, QT Interval</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute values of Weight measurements will be summarized over time for each treatment using a weighing scale in Kg or pounds</measure>
    <time_frame>Within 30 minutes prior to dosing, and then at 15 minutes, 30 minutes, 1hr, 1.5hr, 2hr, 4hr and 5hr after dosing on both Day 1 and Day 8.</time_frame>
    <description>The safety and tolerability of CDX-6114 following single dose oral administration assesed by weight monitoring</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute blood composition values and changes from baseline to the last post-dose time-point will be summarized for each treatment</measure>
    <time_frame>Within 30 minutes prior to dosing, and then at 15 minutes, 30 minutes, 1, 1.5, 2, 4 and 5hours after dosing on both Day 1 and Day 8.</time_frame>
    <description>The safety and tolerability of CDX-6114 following single dose oral administration assesed by laboratory assessments as Haematology and Coagulation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute urine composition values and changes from baseline to the last post-dose time-point will be summarized for each treatment</measure>
    <time_frame>Within 30 minutes prior to dosing, and then at 15 minutes, 30 minutes, 1, 1.5, 2, 4 and 5hours after dosing on both Day 1 and Day 8.</time_frame>
    <description>The safety and tolerability of CDX-6114 following single dose oral administration assesed by routine urinalysis laboratory assessments</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assesment of the incidence of Treatment-Emergent Antibodies</measure>
    <time_frame>Assesments will be done on day 1 and day 8. Blood will be collected for analysis within 30 minutes prior to dosing on Day 1 and Day 8 and again at the End of Study Visit ( through study completion , an avearge of 8 to 10 weeks)</time_frame>
    <description>The safety and tolerability of CDX-6114 following single dose oral administration assesed by assessment for development of anti-CDX-6114 antibodies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>absolute values of height measurements will be summarized over time for each treatment using length measurement scale in centimeters or inches</measure>
    <time_frame>Within 30 minutes prior to dosing, and then at 15 minutes, 30 minutes, 1hr, 1.5hr, 2hr, 4hr and 5hr after dosing on both Day 1 and Day 8.</time_frame>
    <description>The safety and tolerability of CDX-6114 following single dose oral administration assesed by height examination using Lenght scale</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Phenylketonuria</condition>
  <arm_group>
    <arm_group_label>1st Confinement Period in Unit</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Randomized to treatment with either CDX-6114 or matching Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2nd Confinement Period in Unit</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Randomized to treatment with either CDX-6114 or matching Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CDX 6114</intervention_name>
    <description>CDX-6114 for oral administration is formulated in phosphate buffer, which also includes mannitol and poloxamer.The vehicle solution provided is identical to the CDX-6114 oral solution except for the active drug.</description>
    <arm_group_label>1st Confinement Period in Unit</arm_group_label>
    <arm_group_label>2nd Confinement Period in Unit</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Matching Placebo</intervention_name>
    <description>The placebo oral dosing solution will also be supplied as an approximately 240 mL oral solution and will be made up of the phosphate buffer diluent and the caramel flavoring.</description>
    <arm_group_label>1st Confinement Period in Unit</arm_group_label>
    <arm_group_label>2nd Confinement Period in Unit</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  Inclusion criteria&#xD;
&#xD;
               1. Male and female patients between the ages of 18 and 55 years (inclusive) with a&#xD;
                  diagnosis of classical PKU by either a historical blood Phe concentration of &gt;&#xD;
                  1200 mol/L at any time or a genetic diagnosis of PKU.&#xD;
&#xD;
               2. Patients capable of following dietary instructions to maintain protein intake&#xD;
                  stable throughout the study duration based on principal investigator and&#xD;
                  dietician assessment.&#xD;
&#xD;
               3. Patients with a blood Phe concentration &lt; 1200mol/L at screening.&#xD;
&#xD;
               4. Have a body mass index (BMI) between 18.0 and 30.0 kg/m2 inclusive and weigh at&#xD;
                  least 50 kg and no more than 100 kg inclusive.&#xD;
&#xD;
               5. Patients must be in good general health, as determined by the PI or delegate,&#xD;
                  based on a medical evaluation including detailed medical history, full physical&#xD;
                  examination, including blood pressure and pulse rate measurement, 12-lead&#xD;
                  electrocardiogram (ECG) and clinical laboratory tests.&#xD;
&#xD;
               6. Male patients (unless surgically sterilised) and their female spouse/partner(s)&#xD;
                  who are of childbearing potential:&#xD;
&#xD;
                    1. Must agree to stay abstinent (where abstinence is the preferred and usual&#xD;
                       life-style of the patient), starting at screening and continuing throughout&#xD;
                       the clinical study period, and for 90 days after last study drug&#xD;
                       administration.&#xD;
&#xD;
                       Or&#xD;
&#xD;
                    2. Must be using highly effective contraception starting at screening and&#xD;
                       continuing throughout the clinical study period, and for 90 days after last&#xD;
                       study drug administration. Highly effective contraception is defined as&#xD;
                       follows:&#xD;
&#xD;
                  i. Injectable or implantable hormones ii. Intrauterine device iii. Surgical&#xD;
                  sterilisation iv. Sterilisation implant device v. Combined oral contraceptives&#xD;
                  vi. Use of a condom plus oral or injectable or implantable or intrauterine&#xD;
                  contraception&#xD;
&#xD;
                  c. These requirements do not apply to participants in a same sex relationship.&#xD;
&#xD;
               7. Male patients must agree not to donate sperm starting at screening and continuing&#xD;
                  throughout the clinical study period, and for 90 days after last study drug&#xD;
                  administration.&#xD;
&#xD;
               8. Female patients of childbearing potential and their spouse/partner(s):&#xD;
&#xD;
                    1. Must agree not to become pregnant during the clinical study period and for&#xD;
                       30 days after last study drug administration.&#xD;
&#xD;
                    2. Must have a negative serum pregnancy test at screening.&#xD;
&#xD;
                    3. If heterosexually active, must agree to consistently use a form of highly&#xD;
                       effective contraception, starting at screening and continuing throughout the&#xD;
                       clinical study period, and for 30 days after last study drug administration.&#xD;
                       Highly effective contraception is defined as follows:&#xD;
&#xD;
                  i. Injectable or implantable hormones ii. Intrauterine device iii. Surgical&#xD;
                  sterilisation iv. Sterilisation implant device v. Surgical sterilisation of the&#xD;
                  male partner vi. Combined oral contraceptives vii. Use of a condom plus oral or&#xD;
                  injectable or implantable or intrauterine contraception&#xD;
&#xD;
                  Or&#xD;
&#xD;
                  d. Must agree to stay abstinent (where abstinence is the preferred and usual&#xD;
                  life-style of the patient), starting at screening and continuing throughout the&#xD;
                  clinical study period, and for 30 days after last study drug administration.&#xD;
&#xD;
                  e. These requirements do not apply to participants in a same sex relationship.&#xD;
&#xD;
               9. Female patients of non-childbearing potential:&#xD;
&#xD;
                    1. Must have a confirmed clinical history of sterility (e.g. the patient is&#xD;
                       without a uterus).&#xD;
&#xD;
                       Or&#xD;
&#xD;
                    2. Must be postmenopausal as defined as amenorrhea for at least 1 year prior to&#xD;
                       screening and a laboratory confirmed serum follicle stimulating hormone&#xD;
                       (FSH) level ≥ 40mIU/mL or similar value considered to be in the menopausal&#xD;
                       range.&#xD;
&#xD;
              10. Female patients must agree not to breastfeed from screening, throughout the&#xD;
                  clinical study period, and until 90 days after last study drug administration.&#xD;
&#xD;
              11. Female patients must agree not to donate ova from screening, throughout the&#xD;
                  clinical study period, and until 90 days after last study drug administration.&#xD;
&#xD;
              12. Patient must be competent to understand the nature of the study and capable of&#xD;
                  giving written informed consent. Be willing to report for the scheduled study&#xD;
                  visits and communicate to study personnel about adverse events and concomitant&#xD;
                  medication use.&#xD;
&#xD;
              13. Patient agrees not to participate in another interventional study while&#xD;
                  participating in the present clinical study.&#xD;
&#xD;
        Exclusion criteria&#xD;
&#xD;
          1. Female patient who has been pregnant within the 6 months prior to screening or&#xD;
             breastfeeding within the 3 months prior to screening.&#xD;
&#xD;
          2. Evidence or history of clinically significant haematological, renal, endocrine,&#xD;
             pulmonary, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease&#xD;
             (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies&#xD;
             and childhood asthma) at time of screening.&#xD;
&#xD;
          3. Current or chronic history of gastrointestinal illness or conditions interfering with&#xD;
             normal gastrointestinal anatomy or motility. Examples include gastrointestinal bypass&#xD;
             surgery, partial or total gastrectomy, small bowel resection, vagotomy, malabsorption,&#xD;
             Crohn's disease, ulcerative colitis, irritable bowel syndrome (IBS) or celiac sprue.&#xD;
&#xD;
          4. Evidence or history of gastrointestinal symptoms that could lead to the assumption of&#xD;
             an underlying gastrointestinal impairment.&#xD;
&#xD;
          5. Treatment with any anti-platelet and/or anticoagulant medication.&#xD;
&#xD;
          6. Evidence or history of specific food intolerance. Examples include coeliac disease,&#xD;
             severe lactose or dairy food intolerance or a severe intolerance to any&#xD;
             food/ingredient included in the standard breakfast.&#xD;
&#xD;
          7. Any positive result, on screening, for serum hepatitis B surface antigen (HBsAg),&#xD;
             hepatitis C virus antibodies (HCV) or antibodies to human immunodeficiency virus type&#xD;
             1 (HIV-1) and/or type 2 (HIV-2).&#xD;
&#xD;
          8. A positive drug/alcohol result.&#xD;
&#xD;
          9. Patient has a history of exceeding &gt; 21 units of alcohol/week for male patients or &gt;&#xD;
             14 units of alcohol/week for female patients within the 3 months prior to screening.&#xD;
             One unit of alcohol is equivalent to 5 ounces (150 mL) of wine or 12 ounces (360 mL)&#xD;
             of beer or 1.5 ounces (45 mL) of spirits.&#xD;
&#xD;
         10. Patient has a history of regular smoking (daily or most days in a week) or the use of&#xD;
             nicotine products (3 or more nicotine-containing products) who would be unable to&#xD;
             abstain from smoking during the confinement periods in the Phase 1 Unit.&#xD;
&#xD;
         11. Patient has used any recreational drugs of abuse within the 3 months prior to&#xD;
             screening.&#xD;
&#xD;
         12. Patient has a pulse rate ≤ 50 or ≥ 100 bpm; mean systolic blood pressure (SBP) &gt; 140&#xD;
             mmHg; mean diastolic blood pressure (DBP) &gt; 90 mmHg at screening (excluding white-coat&#xD;
             hypertension; therefore, a repeat test showing results within range will be&#xD;
             acceptable).&#xD;
&#xD;
         13. Patient has any clinically significant abnormalities at screening in rhythm,&#xD;
             conduction or morphology of the resting ECG and any clinically significant&#xD;
             abnormalities in the 12-lead ECG, as considered by the PI or delegate, which may&#xD;
             interfere with the interpretation of QTc interval changes including abnormal ST-T wave&#xD;
             morphology.&#xD;
&#xD;
         14. Patient has prolonged QTcF (QT interval corrected for heart rate using Fridericia's&#xD;
             formula) &gt; 450 ms for male patients or &gt; 470 ms for female patients, or a shortened&#xD;
             QTcF &lt; 300 ms or a family history of prolonged QT syndrome, at screening.&#xD;
&#xD;
         15. Patient has any clinically significant abnormalities in clinical chemistry,&#xD;
             haematology, or urinalysis at screening as judged by the PI or delegate, including:&#xD;
             Aspartate aminotransferase (AST), Alanine aminotransferase (ALT), alkaline phosphatase&#xD;
             (ALP), gamma glutamyl transferase (GGT) or Total bilirubin (TBL) more than 2.0 times&#xD;
             above the Upper Limit of Normal (ULN).&#xD;
&#xD;
         16. Plasma donation within the 14 days prior to screening or any whole blood&#xD;
             donation/significant blood loss &gt; 500 mL during the 3 months prior to screening.&#xD;
&#xD;
         17. Treatment with any Investigational Drug or Device/Treatment within the 30 days prior&#xD;
             to the first administration of study drug.&#xD;
&#xD;
         18. Use of any prescribed or non-prescribed medication including herbal medicines,&#xD;
             antacids and analgesics (other than anti-hypertensive drugs, oral contraceptives,&#xD;
             paracetamol or multi-vitamins) for the two weeks prior to the initial administration&#xD;
             of the study medication or up to a minimum of 5 times the half-life of the medication&#xD;
             if it has a long half-life.&#xD;
&#xD;
         19. Known allergy or adverse reaction history to any of the oral dose formulation&#xD;
             components e.g. mannitol.&#xD;
&#xD;
         20. Use of Sapropterin (KUVAN) or pegylated phenylalanine ammonia lyase (Palinzyk) or&#xD;
             SYNB1618 or any Phenylalanine-lowering drug within the last 4 weeks.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Damon Bell</last_name>
    <role>Principal Investigator</role>
    <affiliation>Linear Clinical Research</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tim Heise</last_name>
    <role>Principal Investigator</role>
    <affiliation>Profil Institut für Stoffwechselforschung GmbH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Linear Clinical Research Ltd</name>
      <address>
        <city>Nedlands</city>
        <state>Western Australia</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Profil Institut für Stoffwechselforschung GmbH</name>
      <address>
        <city>Neuss</city>
        <zip>D-41460</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Germany</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>August 3, 2019</study_first_submitted>
  <study_first_submitted_qc>September 6, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 11, 2019</study_first_posted>
  <last_update_submitted>September 11, 2020</last_update_submitted>
  <last_update_submitted_qc>September 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Phenylketonurias</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

